196808-45-4

196808-45-4 structure

Name: Farglitazar
Chemical Name: (2S)-2-(2-benzoylanilino)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid
CAS Number: 196808-45-4
Molecular Formula: C₃₄H₃₀N₂O₅
Molecular Weight: 546.61200
Catalog: Signaling Pathways Cell Cycle/DNA Damage PPAR
Create Date: 2017-07-19 14:43:34
Modify Date: 2024-01-10 10:14:14
Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.

Name	(2S)-2-(2-benzoylanilino)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid
Synonyms	N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine L-Tyrosine,N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl) Farglitazar N-(2-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yI)ethyl]-L-tyrosine (2S)-((2-benzoylphenyl)amino)-3-{4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl}-propionic acid 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID

Description	Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.
Related Catalog	Signaling Pathways >> Cell Cycle/DNA Damage >> PPAR Research Areas >> Metabolic Disease
References	[1]. Chen L, Yang B, McNulty JA, et al. GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J Pharmacol Exp Ther. 2005;312(2):718-725.

Boiling Point	793.7ºC at 760 mmHg
Molecular Formula	C₃₄H₃₀N₂O₅
Molecular Weight	546.61200
Flash Point	433.8ºC
Exact Mass	546.21500
PSA	101.66000
LogP	6.68330
Vapour Pressure	1.45E-26mmHg at 25°C
Index of Refraction	1.639

196810-20-5

196808-45-4

Literature: Henke, Brad R.; Blanchard, Steven G.; Brackeen, Marcus F.; Brown, Kathleen K.; Cobb, Jeff E.; Collins, Jon L.; Harrington Jr., W. Wallace; Hashim, Mir A.; Hull-Ryde, Emily A.; Kaldor, Istvan; Kliewer, Steven A.; Lake, Debra H.; Leesnitzer, Lisa M.; Lehmann, Juergen M.; Lenhard, James M.; Orband-Miller, Lisa A.; Miller, John F.; Mook Jr., Robert A.; Noble, Stewart A.; Oliver Jr., William; Parks, Derek J.; Plunket, Kelli D.; Szewczyk, Jerzy R.; Willson, Timothy M. Journal of Medicinal Chemistry, 1998 , vol. 41, # 25 p. 5020 - 5036

103788-65-4

196808-45-4

Literature: Collins, Jon L.; Blanchard, Steven G.; Boswell, G. Evan; Charifson, Paul S.; Cobb, Jeff E.; Henke, Brad R.; Hull-Ryde, Emily A.; Kazmierski, Wieslaw M.; Lake, Debra H.; Leesnitzer, Lisa M.; Lehmann, Juergen; Lenhard, James M.; Orband-Miller, Lisa A.; Gray-Nunez, Yolanda; Parks, Derek J.; Plunkett, Kelli D.; Tong, Wei-Qin Journal of Medicinal Chemistry, 1998 , vol. 41, # 25 p. 5037 - 5054

1080-06-4

196808-45-4

3580-38-9

196808-45-4

1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	1105205-92-2
930439-75-1	1018584-77-4
1203219-36-6	1375289-11-4